<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Atrial fibrillation and flutter after cardiac surgery
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Atrial fibrillation and flutter after cardiac surgery
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Atrial fibrillation and flutter after cardiac surgery
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Lee, MD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gabriel S Aldea, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Pepper, MA, MChir, FRCS, FESC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. The development of these atrial arrhythmias prolongs hospital stay and is associated with worse long-term prognosis. Other supraventricular arrhythmias, including atrial arrhythmias such as atrioventricular nodal re-entrant tachycardia, are not common in this setting. (See
         <a class="medical medical_review" href="/z/d/html/902.html" rel="external">
          "Atrioventricular nodal reentrant tachycardia"
         </a>
         .)
        </p>
        <p>
         This topic will review the pathogenesis, predictors, clinical course, prevention, and management of AF and atrial flutter occurring after cardiac surgery. Most of the observations on atrial arrhythmias come from patients who developed atrial fibrillation. Our approach to patients with atrial flutter is similar, unless otherwise specified.
        </p>
        <p>
         Ventricular tachyarrhythmias after cardiac surgery and arrhythmias after cardiac transplantation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1584.html" rel="external">
          "Early cardiac complications of coronary artery bypass graft surgery", section on 'Ventricular tachyarrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3518.html" rel="external">
          "Heart transplantation in adults: Arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) and atrial flutter can occur early in the postoperative period or as a late complication of cardiac surgery. A discussion of the mechanisms of AF in the general population is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16402.html" rel="external">
          "Mechanisms of atrial fibrillation"
         </a>
         .)
        </p>
        <p>
         Postoperative AF is likely related to a combination of perioperative factors. These include pre-existing degenerative changes in the atrial myocardium and perioperative conditions that result in abnormalities of several electrophysiologic parameters that promote the development of AF, such as dispersion of atrial refractoriness, increase in phase 3 depolarization, enhanced automaticity, increased interatrial conduction time, and decreased conduction velocity, atrial transmembrane potentials, and fluid and electrolyte shifts [
         <a href="#rid1">
          1-5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1014.html" rel="external">
          "The electrocardiogram in atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some patients develop atrial fibrillation (AF) after cardiac surgery without any apparent predisposing factors, most patients have at least one clinical predictor. Preoperative risk factors include [
         <a href="#rid2">
          2,6-17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing age [
         <a href="#rid6">
          6-12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous history of AF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitral valvular disease, particularly mitral stenosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased left atrial size or cardiomegaly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous cardiac surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic obstructive pulmonary disease (COPD).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated preoperative hemoglobin A1c [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-intensity physical activity in the year prior to surgery [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Being a White person [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity [
         <a href="#rid17">
          17,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of beta blocker or angiotensin converting enzyme inhibitor (ACE inhibitor) treatment or withdrawal of previous treatment. (See
         <a class="local">
          'Prevention of atrial fibrillation and complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preoperative
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         use in some [
         <a href="#rid7">
          7,13
         </a>
         ] but not all studies [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher preoperative plasma concentration of brain natriuretic peptide (BNP) [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-dose
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe right coronary artery stenosis [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preoperative increase in P wave duration on surface (&gt;116 msec) [
         <a href="#rid16">
          16
         </a>
         ] or on signal averaged (&gt;140 msec) ECG  (
         <a class="graphic graphic_figure graphicRef60431" href="/z/d/graphic/60431.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid9">
          9,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/984.html" rel="external">
          "Signal-averaged electrocardiogram: Overview of technical aspects and clinical applications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypokalemia and hypomagnesemia. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol use disorder. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Alcohol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10905838">
         <span class="h1">
          PERIOPERATIVE RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Perioperative factors that have been implicated in the creation of atrial susceptibility to atrial fibrillation (AF) or atrial flutter include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial injury from surgical handling, or cannulation, atrial suture lines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute atrial enlargement from pressure or volume overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate myocardial protection during cardiopulmonary bypass.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long bypass and aortic cross-clamp times.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperadrenergic state (eg, use of postoperative inotropic medications).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary complications, hypoxemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammation [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Inflammation and infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypokalemia and hypomagnesemia [
         <a href="#rid26">
          26-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericardial effusion and pericarditis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxidative stress [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         While mechanisms specific to late AF have not been identified, atrial flutter in these patients is re-entrant and may involve atypical isthmuses between natural barriers, atrial incisions, and scar as well as the cavotricuspid isthmus [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
         Two potential negative risk factors are off-pump coronary artery bypass graft surgery (CABG) and preservation of the anterior fat pad:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Off-pump CABG ─ off-pump CABG is associated with a lower rate of postoperative AF than conventional CABG in some [
         <a href="#rid34">
          34-36
         </a>
         ], but not all [
         <a href="#rid37">
          37
         </a>
         ], studies. (See
         <a class="medical medical_review" href="/z/d/html/1558.html" rel="external">
          "Off-pump and minimally invasive direct coronary artery bypass graft surgery: Clinical use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preservation of the anterior fat pad ─ Some [
         <a href="#rid38">
          38
         </a>
         ], but not all [
         <a href="#rid39">
          39
         </a>
         ], studies have found lower rate of postoperative AF with preservation of the anterior fat pad.
        </p>
        <p>
        </p>
        <p>
         However, none of these risk factors has adequate predictive accuracy to identify the individual patient at risk for postoperative atrial arrhythmia. As a result, risk models that use several factors have been created [
         <a href="#rid6">
          6,40
         </a>
         ]. In one study, a multivariable risk model was derived in a cohort of 3093 patients, and then tested in a validation cohort of 1564 patients [
         <a href="#rid6">
          6
         </a>
         ]. Predictors were identified for any postoperative AF as well as for recurrent AF. The risk score for any postoperative AF successfully stratified patients into groups at low risk (AF incidence &lt;17 percent), medium risk (AF incidence 17 to 52 percent), and high risk (AF incidence &gt;52 percent)  (
         <a class="graphic graphic_table graphicRef53732" href="/z/d/graphic/53732.html" rel="external">
          table 1
         </a>
         ). While we do not routinely use any of these risk models, they highlight the individual risks.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          INCIDENCE AND TIME COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) occurs in 15 to 40 percent of patients in the early postoperative period following coronary artery bypass graft surgery (CABG) [
         <a href="#rid1">
          1,6,41,42
         </a>
         ]. In a 2018 post-hoc analysis of 1812 patients without prior AF in the EXCEL trial, which compared CABG with percutaneous coronary intervention (PCI) for left main coronary artery disease, perioperative AF developed in 18.0 percent of those undergoing CABG (and 0.1 percent of those who received PCI). The incidence increases with increasing age [
         <a href="#rid6">
          6-12,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">
          "Left main coronary artery disease", section on 'Randomized trials'
         </a>
         and
         <a class="local">
          'Adverse outcomes following atrial fibrillation'
         </a>
         below.)
        </p>
        <p>
         AF occurs in 37 to 50 percent after valve surgery [
         <a href="#rid1">
          1,7,8
         </a>
         ], and in as many as 60 percent undergoing valve replacement plus CABG [
         <a href="#rid1">
          1,7
         </a>
         ].
        </p>
        <p>
         Atrial arrhythmias occur most often within the first few days after surgery [
         <a href="#rid1">
          1,6,9,11
         </a>
         ]. In a prospective, multicenter study of 4657 patients undergoing surgery, the majority of first episodes of AF occurred by day two, while the majority of recurrent episodes occurred by day three. Forty-three percent of patients with AF had more than one episode [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Among patients with postoperative AF who have no prior history of atrial arrhythmias, the AF is usually self-limited, as 15 to 30 percent convert within two hours and up to 80 percent in 24 hours [
         <a href="#rid1">
          1,44,45
         </a>
         ]. The mean duration of AF in one report was 11 to 12 hours [
         <a href="#rid45">
          45
         </a>
         ] and more than 90 percent are in sinus rhythm six to eight weeks following surgery [
         <a href="#rid1">
          1,45-47
         </a>
         ]. In one report, for example, only 3 of 116 patients who developed AF after CABG were still in AF at six weeks [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         AF may also occur late after cardiac surgery and the incidence is likely higher than appreciated because many patients may have continued asymptomatic episodes of AF. In a study of over 2000 patients enrolled in cardiac rehabilitation programs after cardiac surgery, 11 percent of patients developed AF (4.4 percent new-onset AF) [
         <a href="#rid48">
          48
         </a>
         ]. Late postoperative AF was associated with adverse outcomes, including heart failure and rehospitalization.
        </p>
        <p>
         Atrial flutter is relatively uncommon compared to atrial fibrillation.
        </p>
        <p class="headingAnchor" id="H266205047">
         <span class="h1">
          CLINICAL MANIFESTATIONS AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of atrial fibrillation or flutter after cardiac surgery may or may not lead to symptoms, such as palpitations, or to a change in the hemodynamic status of the patient. In some individuals with rapid ventricular rates, the blood pressure may fall and potentially be associated with a decline in the urine output.
        </p>
        <p>
         We are not aware of any studies that have systematically characterized the clinical manifestations of postoperative atrial fibrillation (AF) in coronary artery bypass graft surgery patients. In our experience, about 90 percent of these individuals are symptomatic and about 15 percent are hemodynamically unstable.
        </p>
        <p>
         The diagnosis of AF in the hospital is usually not difficult as most patients are on continuous monitoring. All patients should have documentation of the rhythm with a 12-lead electrocardiogram. (See
         <a class="medical medical_review" href="/z/d/html/1014.html" rel="external">
          "The electrocardiogram in atrial fibrillation"
         </a>
         .)
        </p>
        <p>
         Longer-term continuous AF screening may detect more episodes in postoperative cardiac surgery patients who are discharged from the hospital, but more studies are needed before we can recommend this as routine practice (see
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Screening'
         </a>
         ). In a randomized trial of 336 cardiac surgical patients with risk factors for stroke, use of continuous cardiac rhythm monitoring with wearable sensors increased the rate of AF detection within 30 days of discharge. In the intent-to-treat analysis, the primary end point of AF for at least six minutes occurred in 32 patients in the intervention group versus 3 patients in the usual care group (absolute difference, 17.9 percent 95% CI 11.5-24.3 percent) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          ADVERSE OUTCOMES FOLLOWING ATRIAL FIBRILLATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential adverse outcomes after the development of postoperative atrial fibrillation (AF) include stroke, death, and prolongation of hospital stay:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative AF has been associated with an increased risk of
         <strong>
          in-hospital stroke
         </strong>
         in some [
         <a href="#rid7">
          7,41,50-55
         </a>
         ] but not all series [
         <a href="#rid56">
          56,57
         </a>
         ]. In some of these studies, it is possible that underlying comorbidities, such as older age, cerebrovascular or peripheral artery disease, and cardiopulmonary bypass time, are related to in-hospital stroke rather than the arrhythmia itself [
         <a href="#rid43">
          43,52,56-59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least three studies with differing designs have evaluated the
         <strong>
          long-term thromboembolic risk
         </strong>
         of patients with new onset AF after coronary artery bypass graft surgery (CABG) and reached somewhat different conclusions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the EXCEL trial of patients with left main coronary artery disease, new onset AF was an independent predictor of stroke at three years with a rate of 6.6 percent compared with 2.4 percent in patients without AF [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a cohort study of 2108 patients who developed postoperative AF and 8432 patients with nonvalvular AF, the risk of thromboembolism was lower in the former group (18.3 versus 29.7 events per 1000 person-years; adjusted hazard ratio 0.67, 95% CI 0.55-0.81) [
         <a href="#rid60">
          60
         </a>
         ]. In addition, the risk was similar between the groups of patients with and without postoperative AF.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a post-hoc analysis of the ART randomized trial (see
         <a class="medical medical_review" href="/z/d/html/1554.html" rel="external">
          "Coronary artery bypass graft surgery: Graft choices", section on 'Two arterial grafts'
         </a>
         ) comparing bilateral with single internal thoracic artery grafts, the cumulative incidence of cerebrovascular accident was higher in those with postoperative AF relative to those without (6.3 versus 3.7 percent; hazard ratio 1.53, 95% CI 1.06-2.23) [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative AF may identify a subset of patients with increased in-hospital and long-term mortality [
         <a href="#rid6">
          6,25,41,42,62,63
         </a>
         ]. This was suggested by a retrospective study of 6475 patients undergoing CABG at a single institution, 994 (15 percent) of whom developed AF [
         <a href="#rid41">
          41
         </a>
         ]. Patients with AF had significantly greater mortality in-hospital (7.4 versus 3.4 percent) and at four years (26 versus 13 percent). In a case-matched subset of 390 patients, the mortality at five years was significantly higher in those with AF (20 versus 7 percent). On multivariate analysis, postoperative AF was a predictor of long-term mortality in both the retrospective cohort (adjusted odds ratio 1.5) and the case-matched population (odds ratio 3.4).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the EXCEL trial of patients with left main coronary artery disease, new onset AF was an independent predictor of all-cause death at three years with a rate of 11.4 percent compared with 4.3 percent in patients without AF [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study of 1832 patients who underwent CABG, patients with postoperative AF had a higher long-term mortality (2.99 versus 1.34 per 100 person-years; adjusted hazard ratio 2.13, 95% CI 1.45-3.15) during a median follow-up of 51 months [
         <a href="#rid42">
          42
         </a>
         ]. Patients with AF were at higher risk of dying from systemic embolism (adjusted hazard ratio 4.33, 95% CI 1.78-10.52), but not from other causes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative AF is associated with prolongation of the duration of hospitalization, with an increased length of stay between one and six days [
         <a href="#rid7">
          7,11,43,50,51,64,65
         </a>
         ]. New onset AF added approximately six days to the hospital duration in the EXCEL trial of patients with left main coronary artery disease [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          PREVENTION OF ATRIAL FIBRILLATION AND COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend therapies to prevent the development of postoperative atrial fibrillation (AF) in patients undergoing cardiac surgery in an attempt to decrease the duration of hospitalization, to possibly decrease the risk of in-hospital stroke and death, and to decrease the need for anticoagulation in some patients.
        </p>
        <p class="headingAnchor" id="H165339032">
         <span class="h2">
          Prevention of atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of beta blockers,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , atrial pacing, or antioxidant vitamins lowers the risk of postoperative AF [
         <a href="#rid66">
          66
         </a>
         ]. Beta blockers are the best studied of these therapies and we prefer beta blockers to sotalol or amiodarone based on their ease of use and better safety profile. We do not recommend atrial pacing in most cases. There have been no studies comparing the relative efficacy and safety of the traditional antiarrhythmic drugs to antioxidant vitamins.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beta blocker administration is the most widely used prophylactic strategy based on numerous studies showing benefit, ease of use, and cost considerations [
         <a href="#rid1">
          1,6,10,14,64,67-70
         </a>
         ]. Meta-analyses of randomized trials from 2002 and 2004 found that they reduced the risk of AF compared to placebo or no therapy (odds ratios of 0.35, 95% CI 0.26-0.49 and 0.39, 95% CI 0.28-0.52) [
         <a href="#rid64">
          64,71
         </a>
         ]. However, a larger 2006 meta-analysis of 31 trials including 4452 patients performed separate analyses based on whether non-study beta blocker was allowed to be continued or not [
         <a href="#rid72">
          72
         </a>
         ]. When trials confounded by postoperative non-study beta blocker withdrawal were excluded, the effect of beta blockers, although still significant, was less (OR 0.69, 95% CI 0.54-0.87). In addition, other between-trial differences (heterogeneity), such as control group event rates which ranged between 5 and 54 percent, lead us to be unsure of the true magnitude of the benefit from beta blockers in patients who have not previously received them.
        </p>
        <p>
         The issue of whether some beta blockers lower the risk of postoperative AF more successfully than others has not been well studied. In a meta-analysis of randomized trials with 601 patients that compared
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         to
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (succinate and tartrate), carvedilol reduced the incidence of AF (odds ratio 0.50, 95% CI 0.32-0.80) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         The benefit is seen when beta blockers are begun prior to or immediately after surgery. We feel the evidence is not strong enough for us to recommend one beta blocker over another. When possible, we start beta blockers at least 48 hours before surgery, due to concerns about the induction of excessive bradycardia. In addition, some experts are concerned about the increased risk of stroke seen in patients undergoing noncardiac surgery who receive beta blockers soon before surgery. (See
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'Patients with indications for long-term therapy'
         </a>
         .) If a patient is a candidate for initiation of a beta blocker but presents within the 48-hour window, our reviewers have differing approaches. Some will start low dose beta blocker at any time before surgery, while others will wait until after the patient has returned to the intensive care unit and is deemed "stable."
        </p>
        <p>
         The optimal duration of therapy for prevention of postoperative atrial arrhythmias is uncertain, but we often continue the beta blocker until the first postoperative visit. However, many patients who undergo CABG have a clear indication for the long-term use of beta blocker therapy (eg, previous myocardial infarction, left ventricular systolic dysfunction with heart failure, or hypertension).
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Sotalol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is a class III antiarrhythmic agent that has beta blocking activity. A 2011 meta-analysis of 15 randomized studies of patients undergoing cardiac surgery found that sotalol lowered the risk of AF compared to placebo (relative risk [RR] 0.55, 95% CI 0.45-0.66) [
         <a href="#rid74">
          74
         </a>
         ]. Compared to beta blocker, sotalol was more effective (14 versus 23 percent; RR=0.64 [CI, 0.50-0.84]). There was no significant difference in the rates between sotalol and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . Risks of sotalol include torsade de pointes and bradycardia. (See
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is effective when begun 24 to 48 hours before surgery or four hours after surgery [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Amiodarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of our contributors prefer beta blockers to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         for the preoperative prevention of AF.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         lowers the incidence of postoperative AF by about 40 to 50 percent [
         <a href="#rid64">
          64,71,77-82
         </a>
         ]. A 2006 meta-analysis of 18 trials that included nearly 3000 patients found that amiodarone lowered the risk of AF or atrial flutter compared to placebo (odds ratio [OR] 0.48, 95% CI 0.40-0.57) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         However,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is associated with more adverse cardiac events compared to placebo, including bradycardia requiring temporary pacing (5.7 versus 2 percent), and QT prolongation (1.3 versus 0 percent) [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         was directly compared to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in an equivalence trial of 316 hemodynamically stable patients who underwent CABG or valve surgery [
         <a href="#rid83">
          83
         </a>
         ]. The rates of the development of AF were similar (23.9 and 24.8 percent, respectively).
        </p>
        <p>
         A number of different preoperative regimens of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         have been evaluated. It has been given orally one to seven days before surgery [
         <a href="#rid78">
          78,79
         </a>
         ], intravenously immediately after surgery [
         <a href="#rid80">
          80
         </a>
         ], or intravenously for 24 hours followed by oral therapy for four days [
         <a href="#rid81">
          81
         </a>
         ]. The efficacy of these different regimens is illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study randomly assigned 124 patients to oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or placebo for a minimum of seven days prior to elective cardiac surgery, continuing the drug until discharge [
         <a href="#rid78">
          78
         </a>
         ]. The mean total dose of amiodarone administered was 4.8 grams over 13 days (600 mg/day for seven days followed by 200 mg/day until discharge). The amiodarone group had a significant reduction in the incidence of postoperative atrial fibrillation (25 versus 53 percent) without any increase in fatal or nonfatal postoperative complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other oral regimens that have been effective include those that begin five days before surgery or one day before surgery [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The efficacy of postoperative intravenous therapy was documented in the ARCH trial in which 300 patients were randomly assigned to 1 gram of intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         per day for two days or placebo; therapy was begun immediately after CABG [
         <a href="#rid80">
          80
         </a>
         ]. Amiodarone significantly reduced the incidence of atrial fibrillation (35 versus 47 percent for placebo), but did not lower the length of hospitalization (7.6 versus 8.2 days). In another report, intravenous amiodarone begun on call to the operating room and continued for 48 hours, followed by oral amiodarone for three days, also significantly reduced postoperative atrial fibrillation (6 versus 26 percent) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although some have suggested that
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         might be more effective than a beta blocker for the prevention of atrial fibrillation after cardiac surgery [
         <a href="#rid85">
          85
         </a>
         ], this was not confirmed in two meta-analyses [
         <a href="#rid64">
          64,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H444668776">
         <span class="h3">
          Antioxidant vitamins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxidative stress plays a role in ischemia-reperfusion injury, which occurs in open heart surgery. It is also involved in the pathogenesis of AF. Based on limited supportive evidence, as well as the absence of side effects in the short term or significant cost, we believe it is reasonable to give antioxidant vitamins to lower the rate of postoperative AF. (See
         <a class="medical medical_review" href="/z/d/html/1511.html" rel="external">
          "Reperfusion injury of the heart", section on 'Arrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1511.html" rel="external">
          "Reperfusion injury of the heart", section on 'Antioxidant therapy'
         </a>
         and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         A 2011 meta-analysis evaluating five randomized trials comprising 567 patients found that the prophylactic use of the antioxidant vitamins C and E lowered the rate of postoperative AF (odds ratio 0.43, 95% CI 0.21-0.89) [
         <a href="#rid86">
          86
         </a>
         ]. The conclusion of the meta-analysis is limited by the inclusion of small, low-quality studies.
        </p>
        <p>
         Subsequent to the meta-analysis, a small trial randomly assigned 203 patients scheduled to undergo on-pump cardiac surgery to supplementation with n-3 PUFA (1 gram twice daily),
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         (1 g/day), and
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         (400 international units/day) or placebo [
         <a href="#rid87">
          87
         </a>
         ]. n-3 PUFA was started approximately seven days and the vitamins two days before surgery; treatment was continued until hospital discharge. The primary outcome of the occurrence of electrocardiographically confirmed postoperative AF occurred significantly less often in the antioxidant therapy group (9.7 versus 32 percent; relative risk 0.28, 95% CI 0.14-0.56). Due to the small number of events (postoperative AF), as well as the unusually low relative risk found, we believe this trial provides weak evidence in favor of antioxidant vitamins. In addition, we do not believe that the trial, which combined n-3 PUFA with vitamins, changes our view that n-3 PUFA are of no benefit in this setting.
        </p>
        <p>
         If antioxidant vitamins are given to prevent postoperative AF, we suggest using them with the timing and dosing used in the above trial and adding them to another preventative therapy.
        </p>
        <p class="headingAnchor" id="H165339288">
         <span class="h3">
          Atrial pacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial pacing to prevent postoperative AF has been examined in a number of studies. Most [
         <a href="#rid88">
          88-92
         </a>
         ], but not all [
         <a href="#rid81">
          81,93,94
         </a>
         ], showed benefit. In a 2006 meta-analysis, pacing was associated with a significant reduction in AF (OR 0.60, 95% CI 0.47-0.77) [
         <a href="#rid72">
          72
         </a>
         ]. With regard to the optimal pacing strategy (eg, left compared to right atrium or pacing from one or both atria), studies are not definitive [
         <a href="#rid89">
          89-94
         </a>
         ]. Atrial pacing is not considered an invasive procedure in these patients because placement of temporary pacing wires is routinely done at the time of surgery.
        </p>
        <p class="headingAnchor" id="H2709746214">
         <span class="h3">
          Reducing risk of pericardial effusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several methods to reduce the incidence of pericarditis and residual pericardial effusion. One approach we use is placement of a large drain (eg, Blake drain), left in postoperatively until they no longer drain.
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         can be added in this setting to prevent pericarditis when a drain is in place. However, outside of this particular setting, the evidence supporting colchicine's efficacy in reducing postoperative AF is mixed. (See
         <a class="local">
          'Ineffective or possibly effective therapies'
         </a>
         below.)
        </p>
        <p>
         Posterior left pericardiotomy can reduce the incidence of pericardial effusions, which are common triggers for postoperative AF. In patients without a known diagnosis of AF, posterior left pericardiotomy was shown to reduce the incidence of postoperative AF after surgery on the coronary arteries, aortic valve, and/or ascending aorta, without additional risk of postoperative complications [
         <a href="#rid95">
          95
         </a>
         ]. Patients undergoing mitral or tricuspid valve surgeries were not studied. In an adaptive randomized trial of 420 patients, patients assigned posterior left pericardiotomy had a lower incidence of postoperative AF compared with controls (17 versus 32 percent). Patients assigned posterior left pericardiotomy also had a lower incidence of pericardial effusion (12 versus 21 percent). Postoperative major events were similar in the intervention and control groups (3 versus 2 percent), and no pericardiotomy-related complications occurred. Factors that limited generalizability of this study were that it was done in a single center, and there were relatively high rates of postoperative AF, even in a study population at lower risk for AF. We await further studies before recommending this approach for all patients undergoing cardiac surgery.
        </p>
        <p class="headingAnchor" id="H97330379">
         <span class="h3">
          Ineffective or possibly effective therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not recommend any of the following preventative strategies to prevent the development of atrial arrhythmias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         – Digoxin, given preoperatively or postoperatively, does not appear to prevent AF [
         <a href="#rid14">
          14,68,69,96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiarrhythmic drugs
         </strong>
         – Data about the prophylactic use of class I antiarrhythmic drugs to prevent postoperative AF are limited.
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          Procainamide
         </a>
         appears to reduce the number of episodes and duration of AF compared to placebo, but not the incidence of AF [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium channel blockers
         </strong>
         – Calcium channel blockers have uncertain utility in preventing AF after cardiac surgery [
         <a href="#rid68">
          68,99-102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous magnesium
         </strong>
         – Based on the fact that hypomagnesia is a risk factor for AF (see
         <a class="local">
          'Risk factors'
         </a>
         above), magnesium supplementation has been evaluated as a possible therapy to reduce postoperative atrial arrhythmias [
         <a href="#rid103">
          103-108
         </a>
         ]. In a 2006 meta-analysis of 22 trials including 2896 patients, supraventricular arrhythmias occurred significantly less often in patients treated with magnesium compared to controls (odds ratio 0.57, 95% CI 0.42-0.77) [
         <a href="#rid72">
          72
         </a>
         ]. However, there was no effect on hospital stay, perioperative myocardial infarction, or mortality. There was also significant heterogeneity in the size of the effect among trials, and the possibility of publication bias was suggested.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2012 meta-analysis of seven randomized trials (n = 1028), which were felt to have no heterogeneity (I
         <sup>
          2
         </sup>
         = 0), intravenous magnesium reduced the incidence of postoperative AF (relative risk 0.64, 95% CI 0.50-0.83) [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiotensin inhibition
         </strong>
         – Although angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have not previously been considered a specific therapy in patients with AF, a number of observations suggest benefit in nonsurgical settings. (See
         <a class="medical medical_review" href="/z/d/html/935.html" rel="external">
          "ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A significant reduction in the incidence of postoperative AF (20 versus 34 percent) with ACE inhibitors was seen in an observational study of 4657 patients undergoing CABG [
         <a href="#rid6">
          6
         </a>
         ]. However, in a study of 445 patients randomly assigned to placebo,
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         , or
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         one week to four days prior to cardiac surgery, there was no significant difference in the rate of AF after surgery [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective study of 4657 patients undergoing CABG, postoperative AF occurred significantly less often in patients who were treated preoperatively and postoperatively with ACE inhibitors compared to those who were not (20 versus 34 percent, odds ratio 0.62) [
         <a href="#rid6">
          6
         </a>
         ]. In addition, patients who had previously been taking ACE inhibitors and were withdrawn from therapy had a significant increase in risk (46 percent, odds ratio 1.69). The utility of these agents in preventing AF after cardiac surgery remains controversial, however, as other studies have not found a significant benefit [
         <a href="#rid111">
          111-113
         </a>
         ]. A retrospective analysis of 8889 patients undergoing CABG described an increase in major adverse events, including postoperative renal dysfunction as well as AF, in patients receiving preoperative ACE inhibitors [
         <a href="#rid114">
          114
         </a>
         ]. Given the inconsistency in the results among these studies, we do not recommend preoperative ACE inhibitors specifically for prevention of AF in patients undergoing CABG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – Some, but not all, studies have shown that statins lower the rate of postoperative AF [
         <a href="#rid115">
          115,116
         </a>
         ]. A 2015 meta-analysis of 17 randomized trials that compared statin therapy with either placebo or no therapy prior to cardiac surgery (predominantly coronary artery bypass graft surgery) found that such treatment reduced the incidence of postoperative AF (odds ratio 0.54, 95% CI 0.43-0.67), but failed to influence short-term mortality or postoperative stroke [
         <a href="#rid117">
          117,118
         </a>
         ]. However, the meta-analysis pointed out significant limitations of the evidence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The largest randomized trial of preoperative statin therapy was published after the meta-analysis. In the STICS trial, 1922 patients in sinus rhythm scheduled for elective cardiac surgery (87 percent CABG) were randomly assigned to receive perioperative
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         (20 mg daily) or placebo up to eight days before surgery [
         <a href="#rid116">
          116
         </a>
         ]. Any previously prescribed statin was stopped. The rate of the primary outcome of postoperative AF within five days of surgery was similar in both groups (21.1 and 20.5 percent, respectively; odds ratio 1.04, 95% CI 0.84-1.30). Of note, there was no difference in the rate of myocardial injury within 120 hours after surgery. In addition, rosuvastatin was associated with a significant absolute excess in the rate of postoperative acute kidney injury (24.7 versus 19.3 percent; p = 0.005).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based upon established benefits of statin therapy in patients with coronary heart disease, all patients should be on long-term statin. However, for patients who have not started statin therapy prior to CABG, we suggest waiting until after surgery, as there is no clear evidence of benefit from preoperative initiation and possible harm. (See
         <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">
          "Coronary artery bypass surgery: Perioperative medical management", section on 'Statins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         – N-acetylcysteine (NAC) has the potential to protect against the development of perioperative AF due to its antioxidant and anti-inflammatory properties. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This hypothesis was tested in a trial of 115 patients undergoing either CABG or valve surgery who were randomly assigned to either NAC or placebo given one hour before and continued for 48 hours after surgery [
         <a href="#rid119">
          119
         </a>
         ]. The primary end point of an AF episode lasting longer than five minutes during hospitalization was seen in 15 patients and was significantly less common in those who received NAC (5.2 versus 21.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small study designed to evaluate the potential benefit of anti-inflammatory therapy (with NAC or
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         ), 311 patients undergoing cardiac surgery who had no history of AF were randomly assigned to
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , carvedilol, or carvedilol plus NAC [
         <a href="#rid120">
          120
         </a>
         ]. The incidence of postoperative AF was significantly lower in the carvedilol plus NAC group compared to either of the other two interventions (35.9, 24.0, and 8.7 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         – Colchicine reduces the incidence of the postpericardiotomy syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">
          "Post-cardiac injury syndromes", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The issue of whether
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         can reduce the incidence of postoperative AF was addressed in a post hoc substudy. In COPPS, 360 patients undergoing cardiac surgery were randomly assigned to either colchicine 1.0 mg given twice daily on day one followed by 0.5 mg twice daily for one month (the dose was halved in patients &lt;70 kg) or placebo [
         <a href="#rid121">
          121
         </a>
         ]. The first dose was given on postoperative day three. The COPPS Prevention of Atrial Fibrillation (POAF) substudy evaluated outcomes in the 336 patients in sinus rhythm on day three. Colchicine significantly reduced the incidence of postoperative AF (12 versus 22 percent; relative risk reduction 45.5 percent, 95% CI 34.0-94.0 percent) at 30 days. In addition, patients taking colchicine had a significantly shorter in-hospital stay (9.4 versus 10.3 days). There was a trend toward a higher rate of side effects (9.5 versus 4.8 percent) and drug withdrawal (11.8 versus 6.6 percent) with colchicine, but no severe side effects were recorded.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the COPPS-2 trial, 360 patients scheduled for cardiac surgery were randomly assigned to oral
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         or placebo before surgery [
         <a href="#rid122">
          122
         </a>
         ]. The drug was continued for one month after surgery. At three months, there was no significant difference between the two groups in the secondary end point of postoperative AF (34 versus 41 percent, respectively). (See
         <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">
          "Post-cardiac injury syndromes", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We believe there is insufficient evidence to recommend the routine use of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , in part out of a concern that it may negatively impact wound healing and that it leads to gastrointestinal side effects. The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society AF guideline states that colchicine may be considered [
         <a href="#rid123">
          123,124
         </a>
         ]. This was not changed in the 2019 focused update [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          Naproxen
         </a>
         – The potential benefit from naproxen was evaluated in the NAFARM trial, which randomly assigned 161 patients to either naproxen or placebo [
         <a href="#rid126">
          126
         </a>
         ]. There was no significant difference in the rate of postoperative AF (7 versus 15 percent, respectively). The study was stopped early because of an increase in renal failure in the naproxen group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid
         </strong>
         – Based upon the hypothesis that perioperative inflammation may contribute to the development of AF, glucocorticoids have been suggested as prophylactic therapy. (See
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two meta-analyses of small trials in which glucocorticoid treatment was compared to placebo or no treatment in adult cardiac surgery found 26 and 40 percent reductions in the incidence of AF, irrespective of the dose given [
         <a href="#rid127">
          127,128
         </a>
         ]. However, the large, randomized SIRS trial, published after the meta-analyses, found no difference in the rate of new AF [
         <a href="#rid129">
          129
         </a>
         ]. Due to their potential adverse effects on glucose metabolism, wound healing, infection, and the absence of a lowering of the risk of death, we do not recommend the routine use of glucocorticoid therapy to prevent AF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The potential role for glucocorticoid therapy for other outcomes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">
          "Coronary artery bypass surgery: Perioperative medical management", section on 'Glucocorticoid therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H423952309">
         <span class="h2">
          Prevention of complications of atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         While beta blockers,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , and pacing decrease the risk of postoperative AF, the evidence is less robust that the risk of complications such as stroke, death, or length of stay can be prevented. It may be difficult to demonstrate a lowering of the risk of in-hospital stroke with these therapies, as AF is only one risk factor for stroke and as the incidence of stroke is low. (See
         <a class="local">
          'Adverse outcomes following atrial fibrillation'
         </a>
         above.)
        </p>
        <p>
         The best available evidence of the impact of these interventions on the complications of AF comes from a 2006 meta-analysis of heterogenous trials, which noted the following [
         <a href="#rid72">
          72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 29 trials that evaluated length of stay, only
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and pacing shortened the average length of stay (-0.60 days, 95% CI -0.92 to -0.29 and -1.3 days 95% CI -2.55 to -0.08, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 25 trials that reported on the incidence of postoperative stroke, the risk of stroke was decreased from 1.9 to 1.1 percent with treatment (odds ratio 0.63, 95% CI 0.41-0.98).
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         was the only single intervention that significantly lowered the risk of stroke compared to placebo.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H423952316">
         <span class="h2">
          Our approach to prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend preventative therapy to reduce the incidence of postoperative AF, especially in patients at high risk of its development. While the evidence is not robust, prevention of AF may lead to a lowering of the risk of in-hospital stroke and a shortened length of stay. In addition, successful prevention of AF will prevent the need for anticoagulation in some patients. Beta blockers,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , and atrial pacing are significantly more effective than placebo in lowering the rate of postoperative AF [
         <a href="#rid64">
          64,71,72
         </a>
         ]. There is some evidence to support the use of antioxidant vitamins for this purpose.
        </p>
        <p>
         We prefer beta blockers to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         due to lower cost and lower risk of potential side effects and to pacing because of its relative complexity and cost. Amiodarone or sotalol is a reasonable alternative in patients who cannot tolerate beta blockade. If possible, we prefer to start beta blockers prior to CABG. We suggest
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         25 mg twice daily; the dose can be titrated postoperative based on the heart rate and blood pressure. We continue this therapy until the first postoperative visit, unless there is a contraindication.
        </p>
        <p>
         The evidence to support the use of antioxidant vitamins is less robust than that for traditional antiarrhythmic drugs. While awaiting larger randomized trials, we believe it is reasonable to use antioxidant therapy as given in the small randomized trial [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         While prevention with beta blockers,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , or pacing lowers the risk of postoperative atrial fibrillation (AF), many patients still develop AF (see
         <a class="local">
          'Prevention of atrial fibrillation'
         </a>
         above). We are uncertain as to the optimal management of these patients, in part because it is not known whether postoperative AF represents the same arrhythmia as AF occurring without cardiac surgery or if it possesses a similar natural history in terms of portending adverse events.
        </p>
        <p>
         We think the initial management should include correction of predisposing factors such as hypoxemia, electrolyte abnormalities, and hemodynamic instability as well as pain management and withdrawal of stimulating factors such as inotropic agents. Subsequent management relates to the issues of rate control versus rhythm control cardioversion and anticoagulation [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
         Options for management of AF include rate or rhythm control strategies. For patients with atrial flutter, we cardiovert to sinus rhythm prior to discharge in most cases, as this rhythm is more difficult than AF to control medically.
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Rate control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the transient nature of the arrhythmia (see
         <a class="local">
          'Incidence and time course'
         </a>
         above), initial control of the ventricular response rate is an effective and relatively safe strategy in many patients who develop postoperative AF [
         <a href="#rid44">
          44,131
         </a>
         ].
        </p>
        <p>
         Rate control is most commonly achieved with beta blockers. The benefit is partly due to blockade of the augmented postoperative sympathetic state and to prevention of beta blocker withdrawal in patients on beta blockers preoperatively. Intravenous
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         , a beta blocker with a short half-life, can be given for acute rate control if there is a concern for bradyarrhythmias, hypotension, or bronchospasm. Slowing of the ventricular rate in many AF patients receiving inotropic agents postoperatively can be achieved by lowering the dose or discontinuation of these agents.
        </p>
        <p>
         The optimal rate goal for patients with AF after cardiac surgery has not been determined. As these patients vary widely in many clinical features (co-morbidities, need for rapid ventricular rate, etc), we suggest that the optimal ventricular rate be determined on a case by case basis. In many patients, a ventricular rate of less than 110 beats per minute will prevent symptoms such as palpitations and allow for optimal cardiac performance. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy", section on 'Evaluation and goal ventricular rate'
         </a>
         .).
        </p>
        <p>
         Calcium channel blockers and
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         are other atrioventricular (AV) nodal blockers that can control the ventricular rate in AF, but they are not more effective than beta blockers. In patients in whom alternate agents have not been successful in controlling the rate in atrial fibrillation, intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         can be used to slow the ventricular response. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h2">
          Rhythm control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restoration of sinus rhythm from well-tolerated postoperative AF is usually not necessary but occasionally can be beneficial. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
         Restoration of sinus rhythm is indicated in symptomatic patients or in those when rate control is difficult to achieve. An attempt at the restoration of sinus rhythm can be beneficial in patients with a low ejection fraction. In addition, cardioversion in asymptomatic patients may be reasonable when well-tolerated AF occurs near the time of anticipated hospital discharge or when it does not spontaneously terminate within 24 hours, so that oral anticoagulation can be avoided; this is particularly true in patients at high risk of bleeding. We believe that an attempt at cardioversion with either electrical or pharmacologic therapy is reasonable. The choice between the two should be made on local practice and patient conditions.
        </p>
        <p>
         Electrical therapy of AF involves direct current external transthoracic cardioversion and it is effective in approximately 95 percent of cases [
         <a href="#rid132">
          132
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         ). For patients who are refractory to transthoracic cardioversion or when reversion is desirable but the patient's respiratory status makes anesthesia for electrical conversion potentially difficult, pharmacologic therapy with intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         or
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is reasonable. (See
         <a class="local">
          'Sotalol'
         </a>
         above and
         <a class="local">
          'Amiodarone'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         dosing regimens are available in the relevant drug monograph.
        </p>
        <p>
         The efficacy of antiarrhythmic drugs for reversion of postoperative AF is similar to that in AF not related to surgery [
         <a href="#rid133">
          133-141
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1997227199">
         <span class="h2">
          Rate versus rhythm control
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who do not spontaneously revert to sinus rhythm within a few hours, rate control and rhythm control (with or without electrical cardioversion) appear to be comparable strategies [
         <a href="#rid45">
          45,46,142
         </a>
         ]. The choice between the two strategies should take into account patient and physician preferences. Advantages of a rate control strategy include the absence of side effects from drug therapy; disadvantages include a slower resolution of AF, thereby leading to a potentially greater need for anticoagulation at discharge. In many patients, we chose a rhythm control strategy.
        </p>
        <p>
         In a study of patients with no history of AF undergoing cardiac surgery, 523 individuals were randomly assigned to either rate or rhythm control [
         <a href="#rid142">
          142
         </a>
         ]. In the rate control group, the heart rate goal was less than 100 beats per minute and in the rhythm control group,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was given with or without a rate slowing drug. If AF persisted for 24 to 48 hours, electrical cardioversion was recommended. The primary end point was the total number of days of hospitalization within 60 days after randomization. There was no difference between the two groups in the primary outcome (median, 5.1 and 5 days, respectively; p = 0.76). This study had limitations, such as including heterogenous patients and lacking the power to assess effect on death or serious adverse events.
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h2">
          Anticoagulation
         </span>
        </p>
        <p class="headingAnchor" id="H53913896">
         <span class="h3">
          Patients on long-term anticoagulant
         </span>
         <span class="headingEndMark">
          —
         </span>
         For AF patients who are taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or direct oral anticoagulants, we suggest stopping this therapy at least three days before surgery. We restart oral anticoagulant therapy three to five days after surgery. The role of bridging heparin therapy for patients at high risk of an embolic complication while off oral anticoagulant, such as those with AF and a prior embolic event, is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H53914044">
         <span class="h3">
          Patients not taking anticoagulant prior to cardiac surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with AF or atrial flutter, regardless of the setting, are at risk for thromboembolic events; the magnitude of that risk varies based upon a number of factors. Thromboembolic risk is primarily limited to AF or atrial flutter of more than 48 hours duration and is greater in patients with certain high risk features (eg, rheumatic mitral valve disease, previous thromboembolism, hypertension, or heart failure)  (
         <a class="graphic graphic_table graphicRef61615" href="/z/d/graphic/61615.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid130">
          130
         </a>
         ]. The general recommendations for anticoagulation in patients with AF are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">
          "Embolic risk and the role of anticoagulation in atrial flutter"
         </a>
         .)
        </p>
        <p>
         Patients who develop AF after cardiac surgery are at risk of thromboembolic events, including in-hospital stroke. However, in the individual post-surgical patient with an embolic event, the cause may be unclear, as underlying comorbidities are often responsible for such strokes, rather than the arrhythmia itself [
         <a href="#rid56">
          56,64,143
         </a>
         ]. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
         Based on evidence that oral anticoagulant therapy prevents episodes of systemic embolization in the broad population of patients with atrial fibrillation, we believe that such therapy will lead to fewer embolic events in patients with postoperative AF. However, a reduction of events with anticoagulant therapy in this population has never been well studied. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
         As factors other than AF contribute to in-hospital stroke rates, it is not clear that aggressive early anticoagulation (eg, intravenous heparin as a bridge to
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) will reduce the incidence of stroke. In addition, the bleeding risk associated with anticoagulation in the immediate postoperative period (within the first 48 hours in most patients) makes the overall impact of this approach less certain. The potential complications associated with anticoagulation were illustrated in several observational series of patients who were treated with intravenous heparin or oral anticoagulants for a variety of indications [
         <a href="#rid144">
          144-146
         </a>
         ]. When closely monitored, complication rates appear to be low [
         <a href="#rid144">
          144,145
         </a>
         ]. However, one report found a significant increase in large pericardial effusions and tamponade in patients treated with warfarin, particularly when the International normalized ratio (INR) was above the therapeutic target [
         <a href="#rid146">
          146
         </a>
         ]. These large effusions all occurred one week or more after surgery. Thus, when anticoagulation is initiated, the patient must be monitored carefully. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p>
         Similarly, the optimal duration of anticoagulation after hospital discharge is unknown. Among patients with new-onset AF after cardiac surgery, many will revert to and maintain sinus rhythm [
         <a href="#rid1">
          1,45-47
         </a>
         ].
        </p>
        <p>
         Due to the inability to reverse their therapeutic effect, we do not start newer oral anticoagulants in the early postoperative period. There are limited data at present, but this is an evolving strategy that may gain support as our understanding evolves [
         <a href="#rid147">
          147
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H696519681">
         <span class="h3">
          Left atrial appendage closure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence is emerging that the left atrial appendage may play a major role in the development of stroke, and surgical closure may reduce this risk. Patients who have AF who are undergoing cardiac surgery for other indications may benefit from closure. Specific recommendations are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H41">
         <span class="h3">
          Our approach to postoperative anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who develop AF following cardiac surgery, we suggest the following approach to anticoagulation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, we recommend the initiation of oral anticoagulant therapy, but only if bleeding risks are considered acceptable. As the role of direct thrombin and factor Xa inhibitors has not been established for patients with postoperative AF, we suggest that
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         be chosen for most patients (International normalized ratio 2 to 3).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest continuation of anticoagulation for at least four weeks after return to sinus rhythm, particularly if the patient has risk factors for thromboembolism. Longer duration of anticoagulation is recommended by some of our experts in patients with high CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc scores  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 3
         </a>
         ), at low risk for bleeding based on the HAS-BLED score  (
         <a class="graphic graphic_table graphicRef75259" href="/z/d/graphic/75259.html" rel="external">
          table 4
         </a>
         ), or at high risk of AF recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term anticoagulation should be considered for patients who remain in AF or who have paroxysmal AF at four weeks. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest maintaining oral anticoagulation in patients in which a concomitant Cox-Maze procedure has been performed for at least three months, regardless of no postoperative atrial arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">
          "Atrial fibrillation: Surgical ablation", section on 'Maze procedure'
         </a>
         .) After three months with no AF recurrence, anticoagulation may be interrupted, considering the patient risk profile for stroke by the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid148">
          148
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In most cases, we do not use intravenous heparin as a bridge to full oral anticoagulation, as the risk of postoperative bleeding outweighs the small benefit from stroke prevention. For patients with prior systemic or pulmonary embolization or those with a mechanical valve, bridging anticoagulation with heparin may be reasonable.
        </p>
        <p>
         Both intravenous and oral anticoagulation should be monitored closely, as bleeding complications, including pericardial effusion and tamponade increase with excessive anticoagulation.
        </p>
        <p class="headingAnchor" id="H97331689">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines are available from the American College of Cardiology Foundation/American Heart Association, Society of Thoracic Surgeons, American Association of Thoracic Surgery, Canadian Cardiology Society, and the European Society of Cardiology [
         <a href="#rid130">
          130,148,149
         </a>
         ]. Our recommendations are generally consistent with recommendations from these groups.
        </p>
        <p class="headingAnchor" id="H1649012414">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119298.html" rel="external">
          "Society guideline links: Coronary artery bypass graft surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H194220665">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. Most episodes occur by the third postoperative day. (See
         <a class="local">
          'Incidence and time course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse outcomes
         </strong>
         – Potential adverse outcomes of these atrial arrhythmias include a longer length of stay, stroke, or death. (See
         <a class="local">
          'Adverse outcomes following atrial fibrillation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive strategies
         </strong>
         – Beta blockers,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , atrial pacing, reducing the risk of pericardial effusion, and antioxidant vitamins lower the risk of the development of AF and atrial flutter after cardiac surgery and may reduce the length of stay and lower the risk of in-hospital stroke. (See
         <a class="local">
          'Prevention of atrial fibrillation and complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients undergoing cardiac surgery, we recommend treatment with beta blockers (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Beta blocker therapy should be started prior to surgery and continued at least until the first postoperative visit unless contraindicated. We prefer oral
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         25 mg twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients who cannot take beta blockers, either
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         may be used, with the decision based on patient characteristics and physician familiarity. (See
         <a class="local">
          'Our approach to prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest antioxidant therapy in addition to beta blocker therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We start this therapy two days prior to surgery and continue until discharge. We prefer the regimen of
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         (1 gram) and
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         (400 international units), each given daily. (See
         <a class="local">
          'Our approach to prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of postoperative atrial fibrillation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventricular rate control
         </strong>
         – For hemodynamically stable patients who develop postoperative AF, the optimal ventricular rate range should be determined for each patient. In many patients, this rate will be less than 110 beats per minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardioversion
         </strong>
         – For patients who develop well-tolerated postoperative AF and whose rate is well controlled, we suggest not performing cardioversion within the first 24 hours of its development (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Cardioversion may be required within this time frame for those whose AF is poorly tolerated or whose rate is not well controlled. (See
         <a class="local">
          'Rhythm control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Cardioversion in asymptomatic patients may be reasonable when well-tolerated AF is present near the time of anticipated hospital discharge, or when it does not spontaneously terminate within 24 to 48 hours, so that oral anticoagulation can be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anticoagulation
         </strong>
         – For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, and if the perioperative bleeding risks are considered reasonable, we recommend oral anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Our approach to postoperative anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We suggest anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (international normalized ratio 2 to 3) rather than either a direct thrombin or factor Xa inhibitor (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients in whom anticoagulation is started and irrespective of the rhythm status at the time of discharge from the hospital, we suggest continuation of anticoagulation for at least four weeks, rather than stopping at the time of discharge (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H346699792">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff would like to thank Drs. John M. Stulak, Manuel Castellá, and Arie P. Kappetein for their contributions to previous versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg 1993; 56:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsikouris JP, Kluger J, Song J, White CM. Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001; 30:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupont E, Ko Y, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 2001; 103:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaca M, Demirbas MI, Biceroglu S, et al. Prediction of early postoperative atrial fibrillation after cardiac surgery: is it possible? Cardiovasc J Afr 2012; 23:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asher CR, Miller DP, Grimm RA, et al. Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 1998; 82:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaman AG, Archbold RA, Helft G, et al. Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification. Circulation 2000; 101:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendes LA, Connelly GP, McKenney PA, et al. Right coronary artery stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1995; 25:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deliargyris EN, Raymond RJ, Guzzo JA, et al. Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol 2000; 85:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987; 94:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxton AE, Josephson ME. The role of P wave duration as a predictor of postoperative atrial arrhythmias. Chest 1981; 80:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112:3247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinoshita T, Asai T, Suzuki T, et al. Preoperative hemoglobin A1c predicts atrial fibrillation after off-pump coronary bypass surgery. Eur J Cardiothorac Surg 2012; 41:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giaccardi M, Macchi C, Colella A, et al. Postacute rehabilitation after coronary surgery: the effect of preoperative physical activity on the incidence of paroxysmal atrial fibrillation. Am J Phys Med Rehabil 2011; 90:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rader F, Van Wagoner DR, Ellinor PT, et al. Influence of race on atrial fibrillation after cardiac surgery. Circ Arrhythm Electrophysiol 2011; 4:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bramer S, van Straten AH, Soliman Hamad MA, et al. Body mass index predicts new-onset atrial fibrillation after cardiac surgery. Eur J Cardiothorac Surg 2011; 40:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg JS, Zelenkofske S, Wong SC, et al. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation 1993; 88:2618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bramer S, van Straten AH, Soliman Hamad MA, et al. The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting. Ann Thorac Surg 2010; 90:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999; 281:2203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaman AG, Alamgir F, Richens T, et al. The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart 1997; 77:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aglio LS, Stanford GG, Maddi R, et al. Hypomagnesemia is common following cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhart RA, Marx JJ Jr, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991; 17:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008; 51:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma A, Marrouche NF, Seshadri N, et al. Importance of ablating all potential right atrial flutter circuits in postcardiac surgery patients. J Am Coll Cardiol 2004; 44:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. J Am Coll Cardiol 2001; 38:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seiler J, Schmid DK, Irtel TA, et al. Dual-loop circuits in postoperative atrial macro re-entrant tachycardias. Heart 2007; 93:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanasiou T, Aziz O, Mangoush O, et al. Do off-pump techniques reduce the incidence of postoperative atrial fibrillation in elderly patients undergoing coronary artery bypass grafting? Ann Thorac Surg 2004; 77:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002; 359:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almassi GH, Pecsi SA, Collins JF, et al. Predictors and impact of postoperative atrial fibrillation on patients' outcomes: a report from the Randomized On Versus Off Bypass trial. J Thorac Cardiovasc Surg 2012; 143:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings JE, Gill I, Akhrass R, et al. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol 2004; 43:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CM, Sander S, Coleman CI, et al. Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study. J Am Coll Cardiol 2007; 49:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amar D, Shi W, Hogue CW Jr, et al. Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. J Am Coll Cardiol 2004; 44:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008; 118:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmidou I, Chen S, Kappetein AP, et al. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. J Am Coll Cardiol 2018; 71:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soucier RJ, Mirza S, Abordo MG, et al. Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III antiarrhythmic medications. Ann Thorac Surg 2001; 72:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JK, Klein GJ, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study. Am Heart J 2000; 140:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowey PR, Stebbins D, Igidbashian L, et al. Clinical outcome of patients who develop PAF after CABG surgery. Pacing Clin Electrophysiol 2001; 24:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landymore RW, Howell F. Recurrent atrial arrhythmias following treatment for postoperative atrial fibrillation after coronary bypass operations. Eur J Cardiothorac Surg 1991; 5:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosetti M, Tramarin R, Griffo R, et al. Late postoperative atrial fibrillation after cardiac surgery: a national survey within the cardiac rehabilitation setting. J Cardiovasc Med (Hagerstown) 2011; 12:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha ACT, Verma S, Mazer CD, et al. Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2121867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamou SC, Dangas G, Hill PC, et al. Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed GL 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits. N Engl J Med 1988; 319:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor GJ, Malik SA, Colliver JA, et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol 1987; 60:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahtinen J, Biancari F, Salmela E, et al. Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akintoye E, Sellke F, Marchioli R, et al. Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. J Thorac Cardiovasc Surg 2018; 155:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogue CW Jr, Murphy SF, Schechtman KB, Dávila-Román VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation 1999; 100:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotfi A, Wartak S, Sethi P, et al. Postoperative atrial fibrillation is not associated with an increase risk of stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011; 34:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman MF, Wolman R, Kanchuger M, et al. Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Circulation 1996; 94:II74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mickleborough LL, Walker PM, Takagi Y, et al. Risk factors for stroke in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996; 112:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt JH, Xian Y, Peterson ED, et al. Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation. JAMA Cardiol 2018; 3:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetto U, Gaudino MF, Dimagli A, et al. Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery. Circulation 2020; 142:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalavrouziotis D, Buth KJ, Ali IS. The impact of new-onset atrial fibrillation on in-hospital mortality following cardiac surgery. Chest 2007; 131:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxena A, Dinh DT, Smith JA, et al. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 2012; 109:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crystal E, Garfinkle MS, Connolly SS, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004; :CD003611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MH, Deeb GM, Morady F, et al. Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)]. Am J Cardiol 2001; 87:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013; :CD003611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson LW, MacVaugh H 3rd, Tomasello DN, Josephson ME. Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study. Ann Thorac Surg 1980; 29:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84:III236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khuri SF, Okike ON, Josa M, et al. Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting. Am J Cardiol 1987; 60:51D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27:2846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNicolantonio JJ, Beavers CJ, Menezes AR, et al. Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2014; 113:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerin NZ, Jacob S. The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis. Am J Med 2011; 124:875.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 34:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991; 68:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aasbo JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med 2005; 143:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 357:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol 1999; 34:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 2003; 108 Suppl 1:II200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. JAMA 2005; 294:3093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halonen J, Loponen P, Järvinen O, et al. Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial. Ann Intern Med 2010; 153:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerstein J, Soodan A, Qamar M, et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Chest 2004; 126:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon AJ, Greenberg MD, Kilborn MJ, Katz NM. Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery. Am Heart J 2001; 142:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harling L, Rasoli S, Vecht JA, et al. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blommaert D, Gonzalez M, Mucumbitsi J, et al. Effective prevention of atrial fibrillation by continuous atrial overdrive pacing after coronary artery bypass surgery. J Am Coll Cardiol 2000; 35:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg MD, Katz NM, Iuliano S, et al. Atrial pacing for the prevention of atrial fibrillation after cardiovascular surgery. J Am Coll Cardiol 2000; 35:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan K, Lee KL, Chiu CS, et al. Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation 2000; 102:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud EG, Dabir R, Archambeau M, et al. Randomized, double-blind trial of simultaneous right and left atrial epicardial pacing for prevention of post-open heart surgery atrial fibrillation. Circulation 2000; 102:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy T, Fotopoulos G, Walker S, et al. Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting. Circulation 2000; 102:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerstenfeld EP, Hill MR, French SN, et al. Evaluation of right atrial and biatrial temporary pacing for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1999; 33:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung MK, Augostini RS, Asher CR, et al. Ineffectiveness and potential proarrhythmia of atrial pacing for atrial fibrillation prevention after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudino M, Sanna T, Ballman KV, et al. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet 2021; 398:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner B, Rheinlander HF, Decker EL, Cleveland RJ. Digoxin prophylaxis following coronary artery bypass surgery. Clin Pharm 1986; 5:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol 1996; 78:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laub GW, Janeira L, Muralidharan S, et al. Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot study. Crit Care Med 1993; 21:1474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davison R, Hartz R, Kaplan K, et al. Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. Ann Thorac Surg 1985; 39:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EE, Shore DF, Monro JL, Ross JK. Oral verapamil fails to prevent supraventricular tachycardia following coronary artery surgery. Int J Cardiol 1985; 9:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra R, Mishra M, Kler TS, et al. Cardioprotective effects of diltiazem infusion in the perioperative period. Eur J Cardiothorac Surg 1997; 12:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitelberger R, Hannes W, Gleichauf M, et al. Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg 1994; 107:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 2004; 117:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Kut MS, Icer UA, Demirtas MM. Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toraman F, Karabulut EH, Alhan HC, et al. Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2001; 72:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazelrigg SR, Boley TM, Cetindag IB, et al. The efficacy of supplemental magnesium in reducing atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2004; 77:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook RC, Humphries KH, Gin K, et al. Prophylactic intravenous magnesium sulphate in addition to oral {beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a randomized, controlled trial. Circulation 2009; 120:S163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu WJ, Wu ZJ, Wang PF, et al. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials. Trials 2012; 13:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pretorius M, Murray KT, Yu C, et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 2012; 40:2805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shariff N, Zelenkofske S, Eid S, et al. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord 2010; 10:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. Ann Pharmacother 2007; 41:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CM, Kluger J, Lertsburapa K, et al. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 2007; 31:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandeali SJ, Kayani WT, Lee VV, et al. Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting. Am J Cardiol 2012; 110:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng Z, Jayaram R, Jiang L, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016; 374:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liakopoulos OJ, Kuhn EW, Slottosch I, et al. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012; :CD008493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2015; :CD008493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozaydin M, Peker O, Erdogan D, et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008; 29:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013; 34:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011; 124:2290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA 2014; 312:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horbach SJ, Lopes RD, da C Guaragna JC, et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med 2011; 124:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011; :CD005566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon AJ, Kouretas PC, Hopkins RA, et al. Early discharge of patients with new-onset atrial fibrillation after cardiovascular surgery. Am Heart J 1998; 135:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geelen P, O'Hara GE, Roy N, et al. Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. Am J Cardiol 1999; 84:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg 1990; 99:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavaghan TP, Koegh AM, Kelly RP, et al. Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. Br Heart J 1988; 60:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Biasi P, Scrofani R, Paje A, et al. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Eur J Cardiothorac Surg 1995; 9:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985; 54:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz AT, Demírkiliç U, Arslan M, et al. Long-term prevention of atrial fibrillation after coronary artery bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. J Card Surg 1996; 11:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ, Mulji AS, Hoffert DL, et al. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987; 10:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg 1992; 26:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med 2016; 374:1911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollar A, Lick SD, Vasquez KN, Conti VR. Relationship of atrial fibrillation and stroke after coronary artery bypass graft surgery: when is anticoagulation indicated? Ann Thorac Surg 2006; 82:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation 1981; 64:II22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber MA, Hasford J, Taillens C, et al. Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. Am J Cardiol 1990; 66:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993; 14:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson E, Johnke K, Leedahl D, et al. Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis. Am J Surg 2015; 210:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunning J, Nagendran M, Alfieri OR, et al. Guideline for the surgical treatment of atrial fibrillation. Eur J Cardiothorac Surg 2013; 44:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e123.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1011 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11747385" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8379709" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A perspective of postoperative atrial fibrillation in cardiac operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11723451" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171793" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22331249" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prediction of early postoperative atrial fibrillation after cardiac surgery: is it possible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15082699" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A multicenter risk index for atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8379728" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hazards of postoperative atrial arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781973" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10736284" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900634" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8759081" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7798502" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Right coronary artery stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12000056" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3306163" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210589" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972856" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The role of P wave duration as a predictor of postoperative atrial arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286585" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Obesity and risk of new-onset atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612941" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Preoperative hemoglobin A1c predicts atrial fibrillation after off-pump coronary bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21765246" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Postacute rehabilitation after coronary surgery: the effect of preoperative physical activity on the incidence of paroxysmal atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841189" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Influence of race on atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21450475" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Body mass index predicts new-onset atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942351" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8252672" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16764958" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20667326" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10376573" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9227296" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863738" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hypomagnesemia is common following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1993783" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174039" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15261940" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Importance of ablating all potential right atrial flutter circuits in postcardiac surgery patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11499727" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980513" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dual-loop circuits in postoperative atrial macro re-entrant tachycardias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139139" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111144" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Do off-pump techniques reduce the incidence of postoperative atrial fibrillation in elderly patients undergoing coronary artery bypass grafting?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11955537" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22054659" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Predictors and impact of postoperative atrial fibrillation on patients' outcomes: a report from the Randomized On Versus Off Bypass trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028356" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239710" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364327" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998610" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Postoperative atrial fibrillation and mortality after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18824644" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Atrial fibrillation after isolated coronary surgery affects late survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29447735" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565643" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III antiarrhythmic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099990" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11270698" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical outcome of patients who develop PAF after CABG surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1910852" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Recurrent atrial arrhythmias following treatment for postoperative atrial fibrillation after coronary bypass operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21508846" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Late postoperative atrial fibrillation after cardiac surgery: a national survey within the cardiac rehabilitation setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34448866" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10867094" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Atrial fibrillation after beating heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9351718" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Atrial fibrillation after cardiac surgery: a major morbid event?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3263571" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3661408" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15063244" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28890081" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10441102" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Risk factors for early or delayed stroke after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22120735" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Postoperative atrial fibrillation is not associated with an increase risk of stroke or the type and number of grafts: a single-center retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8901723" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8911321" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Risk factors for stroke in patients undergoing coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590304" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33017213" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17356100" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The impact of new-onset atrial fibrillation on in-hospital mortality following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22011556" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15495059" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11274944" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440790" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6965579" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1682069" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347966" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3498356" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093773" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015402" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24332247" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21854895" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10440141" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951075" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16144891" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400034" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11265951" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10440143" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970233" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380589" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21135293" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364747" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685167" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21865202" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23916928" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807440" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Effective prevention of atrial fibrillation by continuous atrial overdrive pacing after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807441" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Atrial pacing for the prevention of atrial fibrillation after cardiovascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942743" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942744" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Randomized, double-blind trial of simultaneous right and left atrial epicardial pacing for prevention of post-open heart surgery atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10993856" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10362203" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Evaluation of right atrial and biatrial temporary pacing for the prevention of atrial fibrillation after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10800794" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Ineffectiveness and potential proarrhythmia of atrial pacing for atrial fibrillation prevention after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34788640" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3485028" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Digoxin prophylaxis following coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8916473" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8403955" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3885884" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3899951" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Oral verapamil fails to prevent supraventricular tachycardia following coronary artery surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332921" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cardioprotective effects of diltiazem infusion in the perioperative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8127110" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15336582" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1404796" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12579104" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11603446" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992881" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The efficacy of supplemental magnesium in reducing atrial fibrillation after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19752363" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Prophylactic intravenous magnesium sulphate in addition to oral {beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22520937" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22824930" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20141642" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341525" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17350856" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22727178" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000910" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27144849" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Perioperative Rosuvastatin in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513959" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Preoperative statin therapy for patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26270008" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Preoperative statin therapy for patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263874" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23232844" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22090167" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25172965" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22017782" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332460" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21563145" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Prophylactic corticosteroids for cardiopulmonary bypass in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26460660" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9539467" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Early discharge of patients with new-onset atrial fibrillation after cardiovascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20802247" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10496451" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2184287" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3146989" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562105" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3893488" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10421596" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8775337" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Long-term prevention of atrial fibrillation after coronary artery bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3499456" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287833" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27043047" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16863754" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Relationship of atrial fibrillation and stroke after coronary artery bypass graft surgery: when is anticoagulation indicated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972824" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2251993" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8299624" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26482512" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23956274" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Guideline for the surgical treatment of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22070836" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
